当前位置: 首页 >> 检索结果
141. Clinical outcomes of potential coeliac disease: a systematic review and meta-analysis.
作者: Mohamed G Shiha.;Annalisa Schiepatti.;Stiliano Maimaris.;NIcoletta Nandi.;Hugo A Penny.;David S Sanders.
来源: Gut. 2024年73卷12期1944-1952页
Potential coeliac disease (PCD) is characterised by positive serological and genetic markers of coeliac disease with architecturally preserved duodenal mucosa. The clinical outcomes and rates of progression to overt coeliac disease in patients with PCD remain uncertain. In this systematic review and meta-analysis, we aimed to evaluate the clinical outcomes of patients with PCD.
142. External validation of serum biomarkers predicting short-term and mid/long-term relapse in patients with Crohn's disease stopping infliximab.
作者: Nicolas Pierre.;Vân Anh Huynh-Thu.;Dominique Baiwir.;Gabriel Mazzucchelli.;Maximilien Fléron.;Lisette Trzpiot.;Gauthier Eppe.;Edwin De Pauw.;David Laharie.;Jack Satsangi.;Peter Bossuyt.;Lucine Vuitton.;Sophie Vieujean.;Jean-Frédéric Colombel.;Marie-Alice Meuwis.;Edouard Louis.; .
来源: Gut. 2024年73卷12期1965-1973页
In patients with Crohn's disease (CD) on combination therapy (infliximab and immunosuppressant) and stopping infliximab (cohort from the study of infliximab diSconTinuation in CrOhn's disease patients in stable Remission on combined therapy with Immunosuppressors (STORI)), the risk of short-term (≤6 months) and mid/long-term relapse (>6 months) was associated with distinct blood protein profiles. Our aim was to test the external validity of this finding in the SPARE cohort (A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy).
143. The road to a world-unified approach to the management of patients with gastric intestinal metaplasia: a review of current guidelines.
作者: Mario Dinis-Ribeiro.;Shailja Shah.;Hashem El-Serag.;Matthew Banks.;Noriya Uedo.;Hisao Tajiri.;Luiz Gonzaga Coelho.;Diogo Libanio.;Edith Lahner.;Antonio Rollan.;Jing-Yuan Fang.;Leticia Moreira.;Jan Bornschein.;Peter Malfertheiner.;Ernst J Kuipers.;Emad M El-Omar.
来源: Gut. 2024年73卷10期1607-1617页
During the last decade, the management of gastric intestinal metaplasia (GIM) has been addressed by several distinct international evidence-based guidelines. In this review, we aimed to synthesise these guidelines and provide clinicians with a global perspective of the current recommendations for managing patients with GIM, as well as highlight evidence gaps that need to be addressed with future research.
144. Environmental impact of single-use versus reusable gastroscopes.
作者: Mathieu Pioche.;Heiko Pohl.;João A Cunha Neves.;Arthur Laporte.;Mikael Mochet.;Jérôme Rivory.;Raphaelle Grau.;Jérémie Jacques.;Daniel Grinberg.;Mathilde Boube.;Robin Baddeley.;Pierre-Jean Cottinet.;Marion Schaefer.;Enrique Rodríguez de Santiago.;Arthur Berger.; .
来源: Gut. 2024年73卷11期1816-1822页
The environmental impact of endoscopy is a topic of growing interest. This study aimed to compare the carbon footprint of performing an esogastroduodenoscopy (EGD) with a reusable (RU) or with a single-use (SU) disposable gastroscope.
145. Age-related patterns of microbial dysbiosis in multiplex inflammatory bowel disease families.
作者: Jonathan P Jacobs.;Elizabeth A Spencer.;Drew S Helmus.;Julianne C Yang.;Venu Lagishetty.;Gerold Bongers.;Graham Britton.;Kyle Gettler.;Pamela Reyes-Mercedes.;Jianzhong Hu.;Amy Hart.;Esi Lamousé-Smith.;Jan Wehkamp.;Carol Landers.;Philip Debbas.;Joana Torres.;Jean-Frederic Colombel.;Judy Cho.;Inga Peter.;Jeremiah Faith.;Jonathan Braun.;Marla Dubinsky.
来源: Gut. 2024年73卷12期1953-1964页
IBD is characterised by dysbiosis, but it remains unclear to what extent dysbiosis develops in unaffected at-risk individuals. To address this, we investigated age-related patterns of faecal and serum markers of dysbiosis in high-risk multiplex IBD families (two or more affected first-degree relatives).
146. Synergistic association of sodium-glucose cotransporter-2 inhibitor and metformin on liver and non-liver complications in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease.
作者: Xianhua Mao.;Xinrong Zhang.;Leslie Kam.;Nicholas Chien.;Rongtao Lai.;Ka-Shing Cheung.;Man-Fung Yuen.;Ramsey Cheung.;Wai-Kay Seto.;Mindie H Nguyen.
来源: Gut. 2024年73卷12期2054-2061页
Type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease (diabetic MASLD) frequently coexist and worsen liver and non-liver outcomes, but effective pharmacological therapies are limited. We aimed to evaluate the long-term effect of sodium-glucose cotransporter-2 inhibitor (SGLT-2i) on liver and non-liver outcomes among patients with diabetic MASLD.
147. Prevalence of steatotic liver disease, advanced fibrosis and cirrhosis among community-dwelling overweight and obese individuals in the USA.
作者: Alexander H Yang.;Monica A Tincopa.;Federica Tavaglione.;Veeral H Ajmera.;Lisa M Richards.;Maral Amangurbanova.;Christian Butcher.;Christie Hernandez.;Egbert Madamba.;Seema Singh.;Ricki Bettencourt.;Bernd Schnabl.;Claude B Sirlin.;Rohit Loomba.
来源: Gut. 2024年73卷12期2045-2053页
There are limited prospective data among overweight and obese individuals on the prevalence of advanced fibrosis, and cirrhosis using advanced MRI-based methods in the USA. The aim of this study was to fill that gap in knowledge by prospectively determining the MRI-based prevalence of steatotic liver disease (SLD) and its subcategories, advanced fibrosis and cirrhosis among overweight and obese individuals residing in the USA.
148. Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease.
作者: Xiao-Dong Zhou.;Seung Up Kim.;Terry Cheuk-Fung Yip.;Salvatore Petta.;Atsushi Nakajima.;Emmanuel Tsochatzis.;Jérôme Boursier.;Elisabetta Bugianesi.;Hannes Hagström.;Wah Kheong Chan.;Manuel Romero-Gomez.;José Luis Calleja.;Victor de Lédinghen.;Laurent Castéra.;Arun J Sanyal.;George Boon-Bee Goh.;Philip N Newsome.;Jiangao Fan.;Michelle Lai.;Céline Fournier-Poizat.;Hye Won Lee.;Grace Lai-Hung Wong.;Angelo Armandi.;Ying Shang.;Grazia Pennisi.;Elba Llop.;Masato Yoneda.;Marc de Saint-Loup.;Clemence M Canivet.;Carmen Lara-Romero.;Rocio Gallego-Duràn.;Amon Asgharpour.;Kevin Kim-Jun Teh.;Sara Mahgoub.;Mandy Sau-Wai Chan.;Huapeng Lin.;Wen-Yue Liu.;Giovanni Targher.;Christopher D Byrne.;Vincent Wai-Sun Wong.;Ming-Hua Zheng.; .
来源: Gut. 2024年73卷11期1883-1892页
Statins have multiple benefits in patients with metabolic-associated steatotic liver disease (MASLD).
149. Association of breast milk-derived arachidonic acid-induced infant gut dysbiosis with the onset of atopic dermatitis.
作者: Suhua Jiang.;Mengyun Cai.;Dingru Li.;Xiangping Chen.;Xiaoqian Chen.;Qitao Huang.;Caimei Zhong.;Xiufeng Zheng.;Dan Zhou.;Zhiyan Chen.;Lin Zhang.;Jessica Yl Ching.;Ailing Chen.;Shaoxia Lu.;Lifang Zhang.;Ling Hu.;Yan Liao.;Ying Li.;Zhihua He.;Jingjing Wu.;Huiyi Huo.;Yongqi Liang.;Wanwen Li.;Yanli Zou.;Wei Luo.;Siew C Ng.;Francis Kl Chan.;Xia Chen.;Yuhua Deng.
来源: Gut. 2024年74卷1期45-57页
The specific breast milk-derived metabolites that mediate host-microbiota interactions and contribute to the onset of atopic dermatitis (AD) remain unknown and require further investigation.
150. Combination of carvedilol with variceal band ligation in prevention of first variceal bleed in Child-Turcotte-Pugh B and C cirrhosis with high-risk oesophageal varices: the 'CAVARLY TRIAL'.
作者: Harsh Vardhan Tevethia.;Apurva Pande.;Rajan Vijayaraghavan.;Guresh Kumar.;Shiv Kumar Sarin.
来源: Gut. 2024年73卷11期1844-1853页
Beta-blockers and endoscopic variceal band ligation (VBL) have been preferred therapies for primary prophylaxis of variceal bleeding. However, the choice of therapy in patients with advanced liver disease with high-risk varices is not clear. A comparison of these therapies alone or in combination to prevent the first variceal bleed in advanced cirrhosis patients was carried out.
151. Impact of prenatal and postnatal maternal IBD status on offspring's risk of IBD: a population-based cohort study.
作者: Linéa Bonfils.;Gry Poulsen.;Manasi Agrawal.;Mette Julsgaard.;Joana Torres.;Tine Jess.;Kristine Højgaard Allin.
来源: Gut. 2025年74卷2期206-213页
In utero exposure to maternal inflammation may impact immune system development and subsequent risk of disease. We investigated whether a maternal diagnosis of IBD before childbirth is linked to a higher risk of IBD in offspring compared with a diagnosis after childbirth. Further, we analysed paternal IBD status for comparison.
152. Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments.
作者: Claudia Campani.;Sandrine Imbeaud.;Gabrielle Couchy.;Marianne Ziol.;Theo Z Hirsch.;Sandra Rebouissou.;Bénédicte Noblet.;Pierre Nahon.;Katia Hormigos.;Sabrina Sidali.;Olivier Seror.;Valerie Taly.;Nathalie Ganne Carrie.;Pierre Laurent-Puig.;Jessica Zucman-Rossi.;Jean-Charles Nault.
来源: Gut. 2024年73卷11期1870-1882页
Circulating tumour DNA (ctDNA) is a promising non-invasive biomarker in cancer. We aim to assess the dynamic of ctDNA in patients with hepatocellular carcinoma (HCC).
153. HBcrAg values may predict virological and immunological responses to pegIFN-α in NUC-suppressed HBeAg-negative chronic hepatitis B.
作者: Andrea Vecchi.;Marzia Rossi.;Camilla Tiezzi.;Paola Fisicaro.;Sara Doselli.;Elena Adelina Gabor.;Amalia Penna.;Ilaria Montali.;Camilla Ceccatelli Berti.;Valentina Reverberi.;Anna Montali.;Simon P Fletcher.;Elisabetta Degasperi.;Dana Sambarino.;Diletta Laccabue.;Floriana Facchetti.;Simona Schivazappa.;Elisabetta Loggi.;Barbara Coco.;Daniela Cavallone.;Elena Rosselli Del Turco.;Marco Massari.;Giuseppe Pedrazzi.;Gabriele Missale.;Gabriella Verucchi.;Pietro Andreone.;Maurizia Rossana Brunetto.;Pietro Lampertico.;Carlo Ferrari.;Carolina Boni.
来源: Gut. 2024年73卷10期1737-1748页
Selected populations of patients with chronic hepatitis B (CHB) may benefit from a combined use of pegylated interferon-alpha (pegIFN-α) and nucleos(t)ides (NUCs). The aim of our study was to assess the immunomodulatory effect of pegIFN-α on T and natural killer (NK) cell responses in NUC-suppressed patients to identify cellular and/or serological parameters to predict better T cell-restoring effect and better control of infection in response to pegIFN-α for a tailored application of IFN-α add-on.
154. Faecal proteomics links neutrophil degranulation with mortality in patients with alcohol-associated hepatitis.
作者: Henriette Kreimeyer.;Carlos G Gonzalez.;Marcos F Fondevila.;Cynthia L Hsu.;Phillipp Hartmann.;Xinlian Zhang.;Peter Stärkel.;Francisco Bosques-Padilla.;Elizabeth C Verna.;Juan G Abraldes.;Robert S Brown.;Victor Vargas.;Jose Altamirano.;Juan Caballería.;Debbie L Shawcross.;Alexandre Louvet.;Michael R Lucey.;Philippe Mathurin.;Guadalupe Garcia-Tsao.;Ramón Bataller.;AlcHepNet Investigators.;David J Gonzalez.;Bernd Schnabl.
来源: Gut. 2024年74卷1期103-115页
Patients with alcohol-associated hepatitis (AH) have a high mortality. Alcohol exacerbates liver damage by inducing gut dysbiosis, bacterial translocation and inflammation, which is characterised by increased numbers of circulating and hepatic neutrophils.
155. Cellular immunotherapies and immune cell depleting therapies in inflammatory bowel diseases: the next magic bullet?
Despite significant advances in biologic and small molecule treatments and the emergence of combination therapies to treat inflammatory bowel diseases (IBD) a large unmet need remains to control intestinal inflammation. New approaches targeting several pathways simultaneously with a favorable safety profile and agents that trigger anti-inflammatory pathways to drive durable resolution of inflammation are needed. This article discusses novel cellular immunotherapies and immune cell depleting therapies in IBD, including CAR-T cell approaches, Tr1 and T regulatory (Treg) cells and cell depleting antibodies such as rosnilimab. These novel approaches have the potential to overcome current therapeutic limitations in the treatment of IBD.
156. Prevalence of irritable bowel syndrome and functional dyspepsia after acute gastroenteritis: systematic review and meta-analysis.
作者: Serena Porcari.;Maria Rosa Ingrosso.;Marcello Maida.;Leonardo Henry Eusebi.;Christopher Black.;Antonio Gasbarrini.;Giovanni Cammarota.;Alexander Charles Ford.;Gianluca Ianiro.
来源: Gut. 2024年73卷9期1431-1440页
Disorders of gut-brain interaction may arise after acute gastroenteritis. Data on the influence of pathogen type on the risk of postinfection IBS (PI-IBS), as on postinfection functional dyspepsia (PI-FD), are limited. We conducted a systematic review and meta-analysis to determine prevalence of PI-IBS or PI-FD after acute gastroenteritis.
157. Untargeted faecal metabolomics for the discovery of biomarkers and treatment targets for inflammatory bowel diseases.
作者: Arnau Vich Vila.;Jingwan Zhang.;Moting Liu.;Klaas Nico Faber.;Rinse K Weersma.
来源: Gut. 2024年73卷11期1909-1920页
The gut microbiome has been recognised as a key component in the pathogenesis of inflammatory bowel diseases (IBD), and the wide range of metabolites produced by gut bacteria are an important mechanism by which the human microbiome interacts with host immunity or host metabolism. High-throughput metabolomic profiling and novel computational approaches now allow for comprehensive assessment of thousands of metabolites in diverse biomaterials, including faecal samples. Several groups of metabolites, including short-chain fatty acids, tryptophan metabolites and bile acids, have been associated with IBD. In this Recent Advances article, we describe the contribution of metabolomics research to the field of IBD, with a focus on faecal metabolomics. We discuss the latest findings on the significance of these metabolites for IBD prognosis and therapeutic interventions and offer insights into the future directions of metabolomics research.
158. Glutamine metabolic competition drives immunosuppressive reprogramming of intratumour GPR109A+ myeloid cells to promote liver cancer progression.
作者: Yang Yang.;Tianduo Pei.;Chaobao Liu.;Mingtao Cao.;Xiaolin Hu.;Jie Yuan.;Fengqian Chen.;Bao Guo.;Yuemei Hong.;Jibin Liu.;Bin Li.;Xiaoguang Li.;Hui Wang.
来源: Gut. 2025年74卷2期255-269页
The metabolic characteristics of liver cancer drive considerable hurdles to immune cells function and cancer immunotherapy. However, how metabolic reprograming in the tumour microenvironment impairs the antitumour immune response remains unclear.
159. KLHL21 suppresses gastric tumourigenesis via maintaining STAT3 signalling equilibrium in stomach homoeostasis.
作者: Xiao-Bo Huang.;Qiang Huang.;Mei-Chen Jiang.;Qing Zhong.;Hua-Long Zheng.;Jia-Bin Wang.;Ze-Ning Huang.;Hua-Gen Wang.;Zhi-Yu Liu.;Yi-Fan Li.;Kai-Xiang Xu.;Mi Lin.;Ping Li.;Zhi-Hong Huang.;Jian-Wei Xie.;Jian-Xian Lin.;Jun Lu.;Jian-Wen Que.;Chao-Hui Zheng.;Qi-Yue Chen.;Chang-Ming Huang.
来源: Gut. 2024年73卷11期1785-1798页
Precancerous metaplasia transition to dysplasia poses a risk for subsequent intestinal-type gastric adenocarcinoma. However, the molecular basis underlying the transformation from metaplastic to cancerous cells remains poorly understood.
160. Cold versus hot snare endoscopic mucosal resection for large (≥15 mm) flat non-pedunculated colorectal polyps: a randomised controlled trial.
作者: Timothy O'Sullivan.;Oliver Cronin.;W Arnout van Hattem.;Francesco Vito Mandarino.;Julia L Gauci.;Clarence Kerrison.;Anthony Whitfield.;Sunil Gupta.;Eric Lee.;Stephen J Williams.;Nicholas Burgess.;Michael J Bourke.
来源: Gut. 2024年73卷11期1823-1830页
Conventional hot snare endoscopic mucosal resection (H-EMR) is effective for the management of large (≥20 mm) non-pedunculated colon polyps (LNPCPs) however, electrocautery-related complications may incur significant morbidity. With a superior safety profile, cold snare EMR (C-EMR) of LNPCPs is an attractive alternative however evidence is lacking. We conducted a randomised trial to compare the efficacy and safety of C-EMR to H-EMR.
|